metformin has been researched along with Pulmonary Fibrosis in 11 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Pulmonary Fibrosis: A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These data suggest that metformin protects against bleomycin-induced pulmonary fibrosis through activation of AMPK and amelioration of TGF-β signaling pathways." | 7.88 | Metformin alleviates bleomycin-induced pulmonary fibrosis in rats: Pharmacological effects and molecular mechanisms. ( Arava, S; Arya, DS; Bhatia, J; Gamad, N; Malik, S; Suchal, K; Tomar, A; Vasisht, S, 2018) |
| "Silicosis is a severe progressive lung disease without effective treatment methods." | 5.72 | Metformin alleviates crystalline silica-induced pulmonary fibrosis by remodeling endothelial cells to mesenchymal transition via autophagy signaling. ( Chang, M; Guan, Y; Jin, Y; Li, H; Li, N; Lin, Z; Liu, N; Wang, Y; Yao, S; Zhao, Y; Zhou, Q, 2022) |
| "Metformin was administered to the mice orally once a day from day 1." | 5.43 | Metformin Reduces Bleomycin-induced Pulmonary Fibrosis in Mice. ( Choi, SM; Jang, AH; Kim, H; Kim, YW; Lee, KH, 2016) |
| "Metformin is a well-established and widely prescribed oral hypoglycemic drug, and has gained attention for its potential anticancer effects." | 5.42 | Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway. ( Chen, H; Han, R; He, Y; Huang, W; Li, K; Li, L; Lin, C; Lu, C; Sun, F; Wang, Y; Zhang, K, 2015) |
| "These data suggest that metformin protects against bleomycin-induced pulmonary fibrosis through activation of AMPK and amelioration of TGF-β signaling pathways." | 3.88 | Metformin alleviates bleomycin-induced pulmonary fibrosis in rats: Pharmacological effects and molecular mechanisms. ( Arava, S; Arya, DS; Bhatia, J; Gamad, N; Malik, S; Suchal, K; Tomar, A; Vasisht, S, 2018) |
| "We aimed to evaluate whether pulmonary fibrosis occurs in type 2 diabetes rat models and whether VD3 can prevent it by inhibiting pyroptosis." | 1.91 | Vitamin D3 alleviates lung fibrosis of type 2 diabetic rats via SIRT3 mediated suppression of pyroptosis. ( Chen, H; Li, M; Li, W; Li, X; Peng, Y; Song, H; Tang, L; Zhang, D; Zhang, Y, 2023) |
| "Silicosis is a severe progressive lung disease without effective treatment methods." | 1.72 | Metformin alleviates crystalline silica-induced pulmonary fibrosis by remodeling endothelial cells to mesenchymal transition via autophagy signaling. ( Chang, M; Guan, Y; Jin, Y; Li, H; Li, N; Lin, Z; Liu, N; Wang, Y; Yao, S; Zhao, Y; Zhou, Q, 2022) |
| "Metformin was administered to the mice orally once a day from day 1." | 1.43 | Metformin Reduces Bleomycin-induced Pulmonary Fibrosis in Mice. ( Choi, SM; Jang, AH; Kim, H; Kim, YW; Lee, KH, 2016) |
| "Metformin is a well-established and widely prescribed oral hypoglycemic drug, and has gained attention for its potential anticancer effects." | 1.42 | Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway. ( Chen, H; Han, R; He, Y; Huang, W; Li, K; Li, L; Lin, C; Lu, C; Sun, F; Wang, Y; Zhang, K, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 5 (45.45) | 2.80 |
| Authors | Studies |
|---|---|
| Li, N | 1 |
| Lin, Z | 2 |
| Zhou, Q | 1 |
| Chang, M | 1 |
| Wang, Y | 4 |
| Guan, Y | 1 |
| Li, H | 1 |
| Zhao, Y | 1 |
| Liu, N | 1 |
| Jin, Y | 1 |
| Yao, S | 1 |
| Li, D | 1 |
| Zhao, A | 1 |
| Zhu, J | 1 |
| Wang, C | 1 |
| Shen, J | 1 |
| Zheng, Z | 1 |
| Pan, F | 1 |
| Liu, Z | 1 |
| Chen, Q | 1 |
| Yang, Y | 1 |
| Tang, L | 1 |
| Zhang, D | 1 |
| Zhang, Y | 1 |
| Peng, Y | 1 |
| Li, M | 1 |
| Song, H | 1 |
| Chen, H | 2 |
| Li, W | 1 |
| Li, X | 1 |
| Yahyapour, R | 1 |
| Amini, P | 1 |
| Saffar, H | 1 |
| Motevaseli, E | 1 |
| Farhood, B | 1 |
| Pooladvand, V | 1 |
| Shabeeb, D | 1 |
| Musa, AE | 1 |
| Najafi, M | 1 |
| Cheng, D | 1 |
| Xu, Q | 1 |
| Li, G | 1 |
| Sun, W | 1 |
| Ma, D | 1 |
| Zhou, S | 1 |
| Liu, Y | 1 |
| Han, L | 1 |
| Ni, C | 1 |
| Gu, X | 1 |
| Han, YY | 1 |
| Yang, CY | 1 |
| Ji, HM | 1 |
| Lan, YJ | 1 |
| Bi, YQ | 1 |
| Zheng, C | 1 |
| Qu, J | 1 |
| Cheng, MH | 1 |
| Gao, J | 1 |
| Wang, J | 1 |
| Han, J | 1 |
| Mei, H | 1 |
| Yu, D | 1 |
| Ding, Q | 1 |
| Zhang, T | 1 |
| Wu, G | 1 |
| Peng, G | 1 |
| Gamad, N | 1 |
| Malik, S | 1 |
| Suchal, K | 1 |
| Vasisht, S | 1 |
| Tomar, A | 1 |
| Arava, S | 1 |
| Arya, DS | 1 |
| Bhatia, J | 1 |
| Li, L | 1 |
| Huang, W | 1 |
| Li, K | 1 |
| Zhang, K | 1 |
| Lin, C | 1 |
| Han, R | 1 |
| Lu, C | 1 |
| Sun, F | 1 |
| He, Y | 1 |
| Choi, SM | 1 |
| Jang, AH | 1 |
| Kim, H | 1 |
| Lee, KH | 1 |
| Kim, YW | 1 |
| Klapholz, L | 1 |
| Leitersdorf, E | 1 |
| Weinrauch, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of Metformin in Prevention and Treatment of Cardiac Fibrosis in PAI-1 Deficient Population[NCT05317806] | Phase 4 | 15 participants (Anticipated) | Interventional | 2022-10-10 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 other studies available for metformin and Pulmonary Fibrosis
| Article | Year |
|---|---|
Metformin alleviates crystalline silica-induced pulmonary fibrosis by remodeling endothelial cells to mesenchymal transition via autophagy signaling.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Autophagy-Related Proteins; Beclin-1; Collagen; H | 2022 |
Inhaled Lipid Nanoparticles Alleviate Established Pulmonary Fibrosis.
Topics: COVID-19; Fibrosis; Humans; Liposomes; Lung; Metformin; Pulmonary Fibrosis; SARS-CoV-2 | 2023 |
Vitamin D3 alleviates lung fibrosis of type 2 diabetic rats via SIRT3 mediated suppression of pyroptosis.
Topics: Animals; Apoptosis; Blood Glucose; Body Weight; Cholecalciferol; Diabetes Mellitus, Experimental; Di | 2023 |
Protective Effect of Metformin, Resveratrol and Alpha-lipoic Acid on Radiation- Induced Pneumonitis and Fibrosis: A Histopathological Study.
Topics: Animals; Antioxidants; Dose-Response Relationship, Drug; Hypoglycemic Agents; Lung; Male; Metformin; | 2019 |
Metformin attenuates silica-induced pulmonary fibrosis via AMPK signaling.
Topics: AMP-Activated Protein Kinases; Animals; Epithelial-Mesenchymal Transition; Fibroblasts; Humans; Lung | 2021 |
Activated AMPK by metformin protects against fibroblast proliferation during pulmonary fibrosis by suppressing FOXM1.
Topics: AMP-Activated Protein Kinases; Animals; Bleomycin; Cell Line; Cell Proliferation; Fibroblasts; Forkh | 2021 |
Metformin Attenuates Radiation-Induced Pulmonary Fibrosis in a Murine Model.
Topics: Animals; Female; Lung Neoplasms; Metformin; Mice; Pulmonary Fibrosis; Radiation Pneumonitis; Radiati | 2017 |
Metformin alleviates bleomycin-induced pulmonary fibrosis in rats: Pharmacological effects and molecular mechanisms.
Topics: Animals; Biomarkers; Bleomycin; Body Weight; Bronchoalveolar Lavage Fluid; Cytokines; Disease Models | 2018 |
Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway.
Topics: Animals; Antineoplastic Agents; Bleomycin; Blotting, Western; Epithelial-Mesenchymal Transition; Flo | 2015 |
Metformin Reduces Bleomycin-induced Pulmonary Fibrosis in Mice.
Topics: Animals; Bleomycin; Bronchoalveolar Lavage Fluid; Collagen Type I; Dose-Response Relationship, Drug; | 2016 |
Leucocytoclastic vasculitis and pneumonitis induced by metformin.
Topics: Female; Humans; Metformin; Middle Aged; Pulmonary Fibrosis; Vasculitis, Leukocytoclastic, Cutaneous | 1986 |